Targeted drug takes aim at NF1-Mutated cancers
NCT ID NCT04439318
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trametinib (a targeted cancer drug, also known as Mekinist)
- What this could lead to
- If it works, this could point toward a treatment option for people with advanced cancers that have an NF1 mutation.
- What could go wrong
- This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like heart rhythm problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Engineered donor cells could outsmart relapsed myeloma
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?